Literature DB >> 26356731

Risk and Protective Factors for Small Intestine Neuroendocrine Tumors: A Prospective Case-Control Study.

Maria Rinzivillo, Gabriele Capurso, Davide Campana, Nicola Fazio, Francesco Panzuto, Francesca Spada, Noemi Cicchese, Stefano Partelli, Paola Tomassetti, Massimo Falconi, Gianfranco Delle Fave.   

Abstract

BACKGROUND: The incidence of small intestine neuroendocrine tumors (SI-NETs) is increasing, but few studies have investigated risk factors for their occurrence, suggesting that family history (FH) of any cancer, smoking and previous cholecystectomy are associated with an increased risk. Such studies investigated small series or examined cancer registries without direct interviews. AIM: We therefore aimed at clarifying risk and protective factors for the occurrence of sporadic SI-NETs. SUBJECTS AND METHODS: We performed a multicenter case-control study. Patients with a histologic diagnosis of SI-NETs were prospectively evaluated, excluding familial syndromes. Controls with non-neoplastic/non-chronic disorders seen at gastrointestinal outpatients clinics were matched for sex and age (4:1). All subjects were directly interviewed by means of a specific questionnaire on potential risk and protective factors. Cases and controls were compared by Fisher's test or Student's t test for categorical or continuous variables. Explanatory variables were analyzed by simple logistic regression analysis. A multiple logistic regression analysis was performed with an Enter model; p < 0.05 was considered significant.
RESULTS: 215 SI-NET patients and 860 controls were enrolled. FH of colorectal cancer (CRC) (8.8 vs. 5.0%) and breast cancer (10.2 vs. 4.8%), heavy smoking (24.7 vs. 14.8%) and drinking >21 alcohol units per week (7.4 vs. 3.8%) were all significantly more frequent in SI-NET patients than in controls. Multivariate analysis showed that FH of CRC (OR 2.23, 95% CI 1.29-3.84, p = 0.003), FH of breast cancer (OR 2.05, 95% CI 1.13-3.69, p = 0.01) and smoking (OR 1.47, 95% CI 1.07-2.03, p = 0.01) and in particular heavy smoking (OR 1.94, 95% CI 1.29-3.84, p = 0.0008) were associated with an increased risk for carcinoid occurrence, while use of aspirin can be considered a protective factor (OR 0.20, 95% CI 0.06-0.65, p = 0.008).
CONCLUSION: FH of colorectal and breast cancer as well as smoking seem to be risk factors for the development of SI-NETs, while use of aspirin might be a protective factor. These factors partially overlap with those associated with CRC, but are different from those previously associated with pancreatic neuroendocrine tumors. These findings may suggest that the mechanisms of carcinogenesis for endocrine cells in different sites can be specific and similar to those of their exocrine counterparts.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26356731     DOI: 10.1159/000440884

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  11 in total

1.  Associations of Tobacco and Alcohol Use with Risk of Neuroendocrine Tumors of the Small Intestine in Utah.

Authors:  Karen Curtin; Lisa A Cannon-Albright; James VanDerslice; Zhe Yu; Kimberly A Herget; Ramya Thota; Deborah W Neklason
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-09-26       Impact factor: 4.254

2.  Epidemiology of neuroendocrine tumors of the appendix in the USA: a population-based national study (2014-2019).

Authors:  Motasem Alkhayyat; Mohannad Abou Saleh; Wendy Coronado; Mohammad Abureesh; Mohammad Zmaili; Thabet Qapaja; Ashraf Almomani; George Khoudari; Emad Mansoor; Gregory Cooper
Journal:  Ann Gastroenterol       Date:  2021-06-14

Review 3.  Classification of pulmonary neuroendocrine tumors: new insights.

Authors:  Giuseppe Pelosi; Angelica Sonzogni; Sergio Harari; Adriana Albini; Enrica Bresaola; Caterina Marchiò; Federica Massa; Luisella Righi; Gaia Gatti; Nikolaos Papanikolaou; Namrata Vijayvergia; Fiorella Calabrese; Mauro Papotti
Journal:  Transl Lung Cancer Res       Date:  2017-10

4.  Genetic associations with neuroendocrine tumor risk: results from a genome-wide association study.

Authors:  Yeting Du; Monica Ter-Minassian; Lauren Brais; Nichole Brooks; Amanda Waldron; Jennifer A Chan; Xihong Lin; Peter Kraft; David C Christiani; Matthew H Kulke
Journal:  Endocr Relat Cancer       Date:  2016-08       Impact factor: 5.678

5.  Risk factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a three-centric case-control study.

Authors:  T Feola; G Puliani; F Sesti; R Modica; R Centello; R Minotta; G Cannavale; S Di Meglio; V Di Vito; R Lauretta; M Appetecchia; A Colao; A Lenzi; A M Isidori; A Faggiano; E Giannetta
Journal:  J Endocrinol Invest       Date:  2022-01-18       Impact factor: 4.256

Review 6.  Neuroendocrine Neoplasms of the Small Bowel and Pancreas.

Authors:  Ashley Kieran Clift; Mark Kidd; Lisa Bodei; Christos Toumpanakis; Richard P Baum; Kjell Oberg; Irvin M Modlin; Andrea Frilling
Journal:  Neuroendocrinology       Date:  2019-09-27       Impact factor: 5.135

Review 7.  Targeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical strategies and future targets.

Authors:  E T Aristizabal Prada; C J Auernhammer
Journal:  Endocr Connect       Date:  2017-11-16       Impact factor: 3.335

8.  Associations between aspirin use and the risk of cancers: a meta-analysis of observational studies.

Authors:  Yan Qiao; Tingting Yang; Yong Gan; Wenzhen Li; Chao Wang; Yanhong Gong; Zuxun Lu
Journal:  BMC Cancer       Date:  2018-03-13       Impact factor: 4.430

9.  The Increasing Incidence of Neuroendocrine Neoplasms Worldwide: Current Knowledge and Open Issues.

Authors:  Roberta Elisa Rossi; Sara Massironi
Journal:  J Clin Med       Date:  2022-06-30       Impact factor: 4.964

10.  Neuroendocrine Tumors: An Analysis of Prevalence, Incidence, and Survival in a Hospital-Based Study in Ecuador.

Authors:  Karime Montes Escobar; Jose Luis Vicente-Villardon; Rosa Elisa Villacís Gonzalez; Paul Humberto Castillo Cordova; Johanna Mabel Sánchez Rodríguez; Melina De la Cruz-Velez; Aline Siteneski
Journal:  Healthcare (Basel)       Date:  2022-08-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.